Setmelanotide
Verdict card (component)
✓ Established | for monogenic obesity (POMC, PCSK1, LEPR deficiency), Bardet-Biedl syndrome, and acquired hypothalamic obesity
An MC4R agonist approved for rare monogenic forms of obesity caused by leptin-melanocortin pathway defects, plus acquired hypothalamic obesity following hypothalamic injury. Marketed as Imcivree. FDA-approved 2020 for POMC, PCSK1, and LEPR deficiency obesity; extended 2022 to Bardet-Biedl syndrome; pediatric indications expanded December 2024 down to age 2 (BBS/POMC/PCSK1/LEPR) and an entirely new acquired hypothalamic obesity indication added (adults and pediatric ≥4 years). Daily subcutaneous injection. The first targeted therapy for monogenic obesity — a small but real population for whom standard obesity therapy doesn’t work because the underlying defect is upstream of normal weight-regulation pathways. The 2024 acquired-hypothalamic-obesity expansion extends the same MC4R-axis logic to patients whose hypothalamic signalling has been damaged by tumor, surgery, or radiation rather than by germline mutation.
Evidence signal row
- ✓ Phase 3 RCT evidence in POMC/LEPR, BBS, and (VENTURE trial) acquired hypothalamic obesity
- ✓ First targeted therapy for monogenic obesity AND for acquired hypothalamic obesity
- ! Indications remain rare — populations are small; eligibility requires genetic confirmation or documented hypothalamic injury
Our verdict (4 sentences)
Setmelanotide is precision medicine for patient populations that previously had nothing — children and adults with proven genetic defects in the leptin-melanocortin pathway, and now patients with acquired hypothalamic obesity from tumor, surgery, or radiation, whose obesity isn’t responsive to lifestyle, bariatric surgery, or GLP-1 therapy because the underlying signal is broken upstream. The Phase 3 evidence (POMC/LEPR, BBS, and now VENTURE in acquired hypothalamic obesity) is solid for the approved indications, and the mechanism makes the population restriction biologically necessary, not just regulatory. The December 2024 expansion to children as young as 2 (for the genetic indications) and the new acquired-hypothalamic-obesity label show the indication scope is still maturing. We rate it Established for the indications it’s approved for; off-label use in non-monogenic, non-hypothalamic obesity is not supported by efficacy evidence and shouldn’t be confused with the GLP-1 / GIP space.
Mechanism
Setmelanotide is a synthetic 8-amino-acid cyclic peptide melanocortin-4 receptor (MC4R) agonist. Designed as a more selective MC4R agonist than melanotan-II, with reduced MC1R, MC3R, and MC5R activity to minimize off-target effects (tanning, sexual side effects).
The leptin-melanocortin pathway is the central signaling axis for appetite and weight regulation in the hypothalamus:
- Leptin (from adipose) signals to the hypothalamic arcuate nucleus
- POMC neurons release α-MSH and other melanocortins
- α-MSH binds MC4R on second-order neurons in the paraventricular nucleus
- MC4R signaling reduces appetite and increases energy expenditure
Defects anywhere in this pathway — POMC deficiency, PCSK1 (which processes POMC), LEPR (the leptin receptor), or downstream effects in BBS — produce severe early-onset obesity that’s largely unresponsive to standard therapies. Setmelanotide bypasses the upstream defect by directly activating MC4R, restoring downstream satiety signaling.
The MC4R selectivity is why setmelanotide doesn’t produce the tanning effects of Melanotan-II (which activates MC1R) — though some focal hyperpigmentation is still possible at therapeutic doses.
What the evidence shows
Phase 3 in POMC and LEPR deficiency (Clément et al, Lancet Diabetes Endocrinol 2020): Open-label, single-arm trial in 31 patients with confirmed genetic diagnoses. ~80% of POMC patients and ~45% of LEPR patients achieved ≥10% weight loss at 1 year. Substantial reductions in hunger scores. Effect sizes are large for the population — the patients in these trials often have BMIs >40 starting in early childhood; double-digit weight loss is clinically transformative.
Phase 3 in Bardet-Biedl syndrome (Haqq et al, Lancet Diabetes Endocrinol 2022): RCT with placebo crossover. ~32% of BBS patients achieved ≥10% weight loss vs much lower placebo response. BBS is a multisystem ciliopathy; obesity is one of several features (others include retinal dystrophy, polydactyly, cognitive impairment, renal anomalies).
Phase 3 in acquired hypothalamic obesity — VENTURE trial (basis for December 2024 FDA expansion): Placebo-controlled RCT in patients with obesity following hypothalamic injury (most commonly post-craniopharyngioma resection or related tumor surgery and radiation). Setmelanotide-treated arm achieved clinically meaningful BMI reduction vs placebo at 1 year. This was the basis for the new acquired-hypothalamic-obesity label and represents the first FDA approval of any drug specifically for this condition — patients who previously had no targeted therapy and who do not respond well to GLP-1s, bariatric surgery, or lifestyle intervention because the hypothalamic damage disrupts the same MC4R-axis signaling that genetic defects do.
Pediatric expansion data (December 2024): Open-label studies in children aged 2–6 with confirmed POMC, PCSK1, LEPR deficiency, or BBS supported expansion of the original genetic indications down to age 2 (previously ≥6 years).
Real-world data: Limited; the patient populations are small enough that registries are still building. Acquired-hypothalamic-obesity real-world data is at the earliest stage given the late-2024 approval.
For non-monogenic, non-hypothalamic obesity: Phase 2 trial in general obesity did not show meaningful weight loss compared to GLP-1-class therapies. The drug has been positioned as indication-specific based on this efficacy gap.
Dosing literature
Approved dosing (subcutaneous, once daily):
- Adults: 2 mg/day, may titrate to 3 mg/day based on tolerance and response
- Pediatric ≥12 years: Up to 3 mg/day, weight-adjusted titration
- Pediatric 6–<12 years: Weight-based titration; max 3 mg/day
- Pediatric 2–<6 years (BBS/POMC/PCSK1/LEPR): Weight-based titration with lower starting dose; expanded to this age group December 2024
- Pediatric ≥4 years (acquired hypathalamic obesity): Weight-based titration; included under the December 2024 label expansion
Daily injection burden is significant for pediatric patients, particularly the youngest cohort now eligible. Long-acting formulations are in development.
Pre-treatment requirements differ by indication:
- Monogenic obesity indications: Genetic testing required to confirm eligible variant in POMC, PCSK1, LEPR, or BBS-associated genes
- *Acquired hypothalamic obesity indication:
Quick Facts
| Also Known As | RM-493, BIM-22493 |
|---|---|
| Sequence | Ac-Arg-Cys(1)-D-Ala-His-D-Phe-Arg-Trp-Cys(1)-Lys-NH2 (cyclic via disulfide bridge between Cys2 and Cys8) |
| Molecular Formula | C49H68N18O9S2 |
| Molecular Weight | 1117.3 Da |
| PubChem CID | 11993702 |
Research Parameters
| Half-Life | Approximately 11 hours |
|---|---|
| Stability | Lyophilized powder is stable when stored as directed. After reconstitution, stability data suggests it should be used immediately or stored refrigerated for a limited period; specific duration post-reconstitution is proprietary. |
| Solubility | Sterile Water for Injection or Bacteriostatic Water for Injection. |
| Storage (Lyophilized) | Store at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Storage (Reconstituted) | Refrigerate at 2°C to 8°C (36°F to 46°F) and use within a defined period (per manufacturer instructions); do not freeze. |
| Typical Research Dose | In clinical research, doses range from 1000 mcg (1 mg) to 3000 mcg (3 mg) daily. |
| Cycle Parameters | In approved clinical use and related research, it is administered as a chronic, daily subcutaneous injection without cyclical breaks, due to the permanent nature of the genetic defects it treats. |
| Amino Acid Count | 13 |
Mechanism of Action
Setmelanotide acts centrally as a potent and selective agonist for the melanocortin-4 receptor (MC4R), which is primarily expressed in the paraventricular nucleus of the hypothalamus. Activation of MC4R is a critical downstream event in the leptin-melanocortin pathway, the principal circuit regulating long-term energy balance, food intake, and energy expenditure.
MC4R Activation: Upon binding, setmelanotide activates MC4R's coupled Gs protein, leading to increased intracellular cyclic AMP (cAMP) production. This activation of specific neuronal populations results in reduced food intake and increased energy expenditure.
Restoration of Pathway Signaling: In conditions like POMC or LEPR deficiency, endogenous agonists (like α-MSH) for MC4R are absent or insufficient. Setmelanotide acts as a replacement agonist, directly stimulating MC4R to restore the anorexigenic (appetite-suppressing) signal, thereby reducing hyperphagia and promoting weight loss.
Selectivity Profile: It exhibits high selectivity for MC4R over other melanocortin receptors (e.g., MC1R, MC3R, MC5R), which is crucial for minimizing off-target effects such as skin pigmentation changes associated with MC1R activation.
Research Applications
Genetic Obesity Syndromes: Research has primarily focused on rare monogenic forms of obesity. Clinical trials have demonstrated profound weight reduction and reduction in insatiable hunger (hyperphagia) in patients with deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR). It represents a paradigm-shifting, etiology-specific treatment for these conditions.
Bardet-Biedl Syndrome: Setmelanotide has shown efficacy in reducing body weight and hunger in patients with Bardet-Biedl syndrome, a ciliopathy with obesity as a core feature, suggesting MC4R pathway dysfunction may be a convergent mechanism in some syndromic obesities.
Common Obesity Investigation: Preclinical and early-phase research explores its potential in more common forms of obesity, particularly in subpopulations hypothesized to have reduced melanocortin pathway tone. Studies investigate its effects on weight, metabolic parameters, and food reward behavior.
Safety & Side Effects
Based on clinical trial data, common side effects include injection site reactions, skin hyperpigmentation, and nausea. Spontaneous penile erection has been reported in male patients. Darkening of pre-existing nevi and new nevus formation have been observed, consistent with mild, off-target MC1R activation. Theoretical concerns include the potential for increased blood pressure and heart rate, which are effects associated with MC4R activation in some preclinical models; monitoring of cardiovascular parameters is standard in clinical use. No significant hepatotoxicity or other organ toxicities have been prominently reported in trials.
Dosage Information
This information is derived from published clinical research protocols and should not be construed as dosing advice. In clinical trials for genetic obesity disorders, setmelanotide is administered via daily subcutaneous injection. The dose is typically titrated: starting at 1.0 mg or 1.5 mg daily for one week, then increasing to 2.0 mg or 3.0 mg daily for the remainder of the treatment period, which in pivotal trials lasted 52 weeks or longer. Administration is intended to be chronic due to the lifelong nature of the underlying conditions.
References
Kühnen, P., et al. 'Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.' New England Journal of Medicine, vol. 375, 2016, pp. 240-246.
Clement, K., et al. 'Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.' The Lancet Diabetes & Endocrinology, vol. 8, no. 12, 2020, pp. 960-970.
Haws, R., et al. 'Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.' Diabetes, Obesity and Metabolism, vol. 22, no. 11, 2020, pp. 2133-2140.
Collet, T.H., et al. 'Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency.' Molecular Metabolism, vol. 6, no. 10, 2017, pp. 1321-1329.
Markham, A. 'Setmelanotide: First Approval.' Drugs, vol. 81, 2021, pp. 397-403.
Fani, L., et al. 'The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options.' International Journal of Obesity, vol. 38, 2014, pp. 163-169.